;
Skip to main content
Home > SciBX > Cover Story

Chronological Index of : Cover Story

 Current Issue
  • Contaminating cancer genomes

    Two European teams have pinpointed a DNA-protective enzyme as a chemically tractable target whose inhibition kills cancer cells by accelerating DNA damage. Both groups have identified small molecule inhibitors of the …

    Published on 4/17/2014
  • Pre-EMP-tive strike against GBM

    UCLA researchers have treated glioblastoma in mice by inhibiting EMP2. The findings open up a new indication for spinout Paganini, which has a mAb against the target in development for triple-negative breast cancer.

    Published on 4/10/2014
  • Table 1: EMP2's downstream crowd

    Cover Story: Pre-EMP-tive strike against GBM Table 1. EMP2's downstream crowd. University of California, Los Angeles researchers have shown that in mouse models of glioblastoma multiforme (GBM) and breast cancer, …

    Published on 4/10/2014
  • Critical mass in diabetes

    A University of Bremen group has found a new target-STK4-that can increase beta cell mass and may provide an alternative to invasive islet cell transplants to treat diabetes. The team will need to rule out long-term …

    Published on 4/3/2014
  • A bitter taste for sinus infections

    A University of Pennsylvania study has shown that bitter taste agonists stimulate the release of antimicrobial peptides in the sinuses, suggesting a new way to treat chronic rhinosinusitis. Although taste receptor-…

    Published on 3/27/2014
  • A liver divided

    Three independent teams have directly converted human fibroblasts to liver cells and eliminated a proliferation barrier from stem cell-based protocols.

    Published on 3/20/2014
  • Killer targets in metastasis

    An international team has found a new pathway in NK cells that leads to the rejection of metastatic tumors. It remains unclear which components of the pathway will make the best targets.

    Published on 3/13/2014
  • Box 1: The development and validation of LDC1267

    Cover Story: Killer targets in metastasis Box 1. The development and validation of LDC1267. In 2008, Axel Ullrich and co-workers published evidence that the TAM receptor family protein AXL receptor tyrosine kinase (…

    Published on 3/13/2014
  • Figure 1: Strategies to activate antitumor NK cells

    Cover Story: Killer targets in metastasis Figure 1. Strategies to activate antitumor NK cells. NK activation occurs downstream of killer cell lectin-like receptor subfamily K member 1 (KLRK1; CD314; NKG2D). In Nature…

    Published on 3/13/2014
  • Liver X receptor marks the spot

    A New York team and Rgenix have found that LXR agonists can treat metastatic melanoma. The findings open up new therapeutic real estate for LXR agonists that pharma companies discontinued in cardiovascular disease.

    Published on 3/6/2014
  • Table 1: Participants in the NIH AMP consortium

    Cover Story: AMPlifying targets Table 1. Participants in the NIH AMP consortium. The NIH has formed a public-private partnership, called the Accelerating Medicines Partnership (AMP), with industry and not-for-profit …

    Published on 2/27/2014
  • AMPlifying targets

    The NIH has joined with over 15 companies and not-for-profit organizations to create the Accelerating Medicines Partnership, a public-private partnership focused on discovering new targets and biomarkers for 4 diseases.…

    Published on 2/27/2014
  • Europe's upwelling

    SciBX's third annual comprehensive analysis of public-private partnerships and early stage venture financing activity shows that Europe's PPP activity in 2013 surpassed that of the U.S. in dramatic fashion.

    Published on 2/20/2014
  • Figure 1: Regional breakdown of companies and institutions in public-private partnerships, 2011-2013

    Cover Story: Europe's upwelling Figure 1. Regional breakdown of companies and institutions involved in public-private partnerships, 2011-2013. The number of disclosed public-private partnerships (PPPs) worldwide by …

    Published on 2/20/2014
  • Figure 2: Regional leaders in public-private partnerships

    Cover Story: Europe's upwelling Figure 2. Regional leaders in public-private partnerships. A breakdown of companies and institutions involved in public-private partnerships (PPPs) in the top five U.S. states (I), top…

    Published on 2/20/2014
  • Figure 3: Therapeutic areas covered by public-private partnerships and seed or series A financings

    Cover Story: Europe's upwelling Figure 3. Therapeutic areas covered by public-private partnerships and seed or series A financings. A breakdown of therapeutic areas covered by public-private partnerships (PPPs) in …

    Published on 2/20/2014
  • Table 1: Leaders in the number of public-private partnerships

    Cover Story: Europe's upwelling Table 1. Leaders in the number of public-private partnerships. The European Commission and Cancer Research UK took the top positions with respect to the number of disclosed public-…

    Published on 2/20/2014
  • Table 2: Top public-private partnerships in 2013 by value

    Cover Story: Europe's upwelling Table 2. Top public-private partnerships in 2013 by value. Public-private partnerships (PPPs) that include grants, awards and/or other types of direct funding support from national …

    Published on 2/20/2014
  • Table 3: Largest series A financing rounds for companies founded in 2013

    Cover Story: Europe's upwelling Table 3. Largest series A financing rounds for companies founded in 2013. Unlike in 2011 and 2012, European biotechs boasted some of the largest series A rounds last year. Table …

    Published on 2/20/2014
  • Curb your fatty acids

    A UCSF team has uncovered a pathway for regulating absorption of fatty acids that yielded MFGE8 as a new obesity target. The team is working on inhibitors of the integrin ligand or its receptors for use in the …

    Published on 2/13/2014
  • Germinating MALT1

    AstraZeneca has teamed up with the Flanders Institute for Biotechnology and the Centre for Drug Design and Discovery to make a play for inhibitors of MALT1. The announcement caps five years of progress toward validating…

    Published on 2/6/2014
  • BBB-conquering antibodies

    Roche has developed an improved transferrin receptor-targeting strategy that dramatically increases delivery of biologics to the brain. The team showed proof of concept in mice and now needs to adapt the system for …

    Published on 1/30/2014
  • Regeneron revisits genomics

    Regeneron has opened a genetics center tasked with analyzing the genomes of at least 100,000 patients in the next 5 years. The company hopes the volume of data, diversity of the patient population and rapid validation …

    Published on 1/23/2014
  • Putting on the brakes

    A group at Memorial Sloan-Kettering Cancer Center has developed T cells that express an inhibitory chimeric antigen receptor, or iCAR, in addition to a cancer-specific CAR to prevent healthy cells from activating T cell…

    Published on 1/16/2014
  • Box 1: Revving up T cells

    Cover Story: Putting on the brakes Box 1. Revving up T cells. Michel Sadelain, director of the Memorial Sloan-Kettering Cancer Center's Center for Cell Engineering, previously teamed with researchers from the …

    Published on 1/16/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993